Literature DB >> 7955903

Exercise haemodynamics in the normotensive and the hypertensive subject.

P Palatini.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7955903     DOI： 10.1042/cs0870275

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN： 0143-5221            Impact factor:   6.124


× No keyword cloud information.
  7 in total

Review 1.  Relevance of heart rate as a risk factor in hypertension.

Authors:  P Palatini; S Julius
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

2.  Atenolol blunts blood pressure increase during dynamic resistance exercise in hypertensives.

Authors:  Ricardo S Gomides; Luiz A R Costa; Dinoélia R Souza; Andréia C C Queiroz; João R C Fernandes; Kátia C Ortega; Décio Mion Junior; Taís Tinucci; Cláudia L M Forjaz
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Drug doping in senior Australian rules football: a survey for frequency.

Authors:  K J Hardy; J J McNeil; A G Capes
Journal:  Br J Sports Med       Date:  1997-06       Impact factor: 13.800

Review 4.  Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs.

Authors:  P Palatini
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms.

Authors:  Paolo Palatini
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Effects of Exercise on the Structure and Circulation of Choroid in Normal Eyes.

Authors:  Takamasa Kinoshita; Junya Mori; Natsuki Okuda; Hiroko Imaizumi; Masanori Iwasaki; Miho Shimizu; Hirotomo Miyamoto; Kei Akaiwa; Kentaro Semba; Shozo Sonoda; Taiji Sakamoto; Yoshinori Mitamura
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

7.  Exaggerated Exercise Blood Pressure Response and Future Cardiovascular Disease.

Authors:  Nikolaos Tzemos; Pitt O Lim; Isla S Mackenzie; Thomas M MacDonald
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-03       Impact factor: 3.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.